A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003882
Abstract: Background In lymphoid malignancies, the introduction of chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) has achieved remarkable clinical success. However, such immunotherapeutic strategies are not yet established for acute myeloid leukemia (AML),… read more here.
Keywords: aml; cln 049; novel igg; treatment ... See more keywords
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-201478
Abstract: Background: Substantial unmet medical need remains for patients with acute myeloid leukemia (AML) who often have minimal residual disease (MRD) at the end of induction therapy that drives disease recurrence. Emerging approaches to improve outcomes… read more here.
Keywords: treatment; dose expansion; cln 049; dose escalation ... See more keywords